ICER’s Biopharma Members: Why They Joined And What They Get
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
You may also be interested in...
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.
Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.